109134 ⎘
Structure or type of the nucleic acid; Type of nucleic acid; Antisense targeting other non-coding nucleic acids, e.g. antagomirs
MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes
#302CHIMERIC RNA OLIGONUCLEOTIDES AND USES THEREOF
#303Modified nucleic acids, hybrid guide RNAs, and uses thereof
#304Compositions and methods for the treatment of hypercholesterolemia
#305RNA-based regulatory technologies for miRNA sensors
#306Methods and pharmaceutical compositions for the treatment of cystic fibrosis
#307Technique for treating cancer using structurally-reinforced S-TuD
#308Compositions and methods for modulation of IKBKAP splicing
#309Method for blocking miRNA
#310Recombinant AAV variants and uses thereof
#311Arrays of memory cells individually comprising a capacitor and an elevationally-extending transistor, methods of forming a tier of an array of memory cells, and methods of forming an array of memory cells individually comprising a capacitor and an elevationally-extending transistor
#312Methods of using PVT1 exon 9 to diagnose and treat prostate cancer
#313IncRNAS for therapy and diagnosis of angiogenesis
#314Conjugated antisense compounds and their use
#315Synthetic nanostructures including nucleic acids and/or other entities
#316OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF
#317Treatment of angiogenesis disorders
#318METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#319Modulation of Lnc05 expression
#320IMMUNOMODULATION BY CONTROLLING ELR+ PROINFLAMMATORY CHEMOKINE LEVELS WITH THE LONG NON-CODING RNA UMLILO
#321COMPOUNDS AND METHODS FOR USE IN DYSTROPHIN TRANSCRIPT
#322COMPOUNDS AND METHODS FOR MODULATION OF TRANSCRIPT PROCESSING
#323Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
#324Compounds and methods for enhanced cellular uptake
#325Modulators of human KAI1 metastasis suppressor gene, methods and uses thereof
#326Microrna inhibitors as anti-cancer therapeutics
#327Methods for enhancing utrophin production via inhibition of microRNA
#328MICRORNAS IN NEURODEGENERATIVE DISORDERS
#329Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy
#330Inhibiting microRNA to prevent development of essential hypertension
#331Compound and method for treating myotonic dystrophy
#332Antisense oligomers targeting HOXB-AS3 long non-coding RNA
#333Compositions and methods for treatment of cardiac diseases
#334Modulation of huntingtin expression
#335C/EBPα short activating RNA compositions and methods of use
#336Modulation of micrornas against myotonic dystrophy type 1 and antagonists of micrornas therefor
#337Von Willebrand Factor (VWF)—targeting agents and methods of using the same
#338NOVEL USE OF KIRREL2 AND KIRREL2 INHIBITOR
#339Materials and methods for modifying the activity of T cells
#340Modulators of vault RNAs for use in the treatment of diseases
#341MIR-92 INHIBITORS AND USES THEREOF
#342AAV-based treatment of cholesterol-related disorders
#343Compositions comprising reversibly modified oligonucleotides and uses thereof
#344Methods of Manipulating the Fate of Cells
#345Compositions and methods for treating cancer
#346Targeting MicroRNAs for Metabolic Disorders
#347Methods for treatment of polycystic kidney disease
#348MicroRNA Compounds and Methods for Modulating MIR-122
#349Modulating the cellular stress response
#350Compositions and methods for selective inhibition of grainyhead-like protein expression
#351APTAMER-BASED ANALYTE ASSAYS
#352LNCRNA MEG3 for therapy and diagnosis of cardiac remodelling
#353Arrays of memory cells individually comprising a capacitor and an elevationally-extending transistor, methods of forming a tier of an array of memory cells, and methods of forming an array of memory cells individually comprising a capacitor and an elevationally-extending transistor
#354MIR-29 MIMICS AND USES THEREOF
#355NOVEL NON-CODING RNA, CANCER TARGET AND COMPOUNDS FOR CANCER TREATMENT
#356Inhibitors of metastasis
#357Modulation of adipose tissue macrophage phenotype by use of MicroRNA-30
#358Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
#359Construction of MicroRNA gene-mediated novel tissue engineered nerve and applications thereof in repairing nerve defect
#360Method for promoting muscle regeneration
#361Oligonucleotide compositions and uses thereof
#362RNA nanoparticles for brain tumor treatment
#363Compositions and methods for treating diabetic retinopathy
#364DOWNREGULATING MIR-132 FOR THE TREATMENT OF LIPID RELATED DISORDERS
#3653′-UTR sequences for stabilization of RNA
#366Pharmaceutical Composition
#367COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF CANCER USING SLNCR ISOFORMS
#368Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#369Multimeric oligonucleotide compounds
#370TLX and MIR-219 as potential therapeutic targets for neurodevelopmental disorders
#371POLYNUCLEOTIDE-POLY(DIOL) CONJUGATES, PROCESS OF PREPARATION AND USES THEREOF
#372COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#373METHODS FOR IDENTIFYING AND TARGETING NON-CODING RNA SCAFFOLDS
#374Stabilized thrombin
#375Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
#376Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
#377Methods for reactivating genes on the inactive X chromosome
#378Materials and methods for the treatment of vascular disease
#379TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#380MODULATION OF ENHANCER RNA MEDIATED GENE EXPRESSION
#381Genome editing for treating glioblastoma
#382Compositions and methods for modulation of IKBKAP splicing
#383Method for determining decrease in functions of hippocampus by using correlation between micro RNA and NMDA receptor, method for inhibiting decrease in functions, and method for screening for inhibitors of decrease in functions
#384Methods and compositions for managing vascular conditions
#385THERAPEUTIC AND DIAGNOSTIC MOLECULES
#386MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
#387Micro-RNAs as biomarkers for subconcussive and concussive injury and therapeutic applications
#388MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#389Methods of reducing expression of X-inactivation escapee genes and autosomal genes
#390Oncolytic viral vectors and uses thereof
#391Targeted self-assembly of functionalized carbon nanotubes on tumors
#392RNA interactome of polycomb repressive complex 1 (PRC1)
#393Compounds and methods for modulating C90RF72
#394Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
#395MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#396Targeting MicroRNAs for the Treatment of Fibrosis
#397Methods for Treatment of Alport Syndrome
#398Non-coding RNAs linked to immortality and associated methods and compositions
#399TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE
#400INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF
#401Method for altering the functional state of mRNA allowing its selective and specific recognition
#402Methods and compositions for modulating gene expression
#403Compositions and methods for modulating apolipoprotein (a) expression
#404Compositions and methods for modulating apolipoprotein C-III expression
#405Oligonucleotide-based inhibitors comprising locked nucleic acid motif
#406Modulation of SMN expression
#407Short non-coding protein regulatory RNAs (sprRNAs) and methods of use
#408Motor neuron-specific expression vectors
#409SARNA COMPOSITIONS AND METHODS OF USE
#410Method for identification of anti-HIV human miRNA mimics and miRNA inhibitors and anti-HIV pharmaceutical compounds
#411Targeting microRNAs for metabolic disorders
#412MIR-19 MODULATORS AND USES THEREOF
#413Polycomb-associated non-coding RNAs
#414Methods and compositions to treat liver diseases and conditions
#415MiR-92 inhibitors and uses thereof
#416Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#417METHODS FOR TREATING TUMORS
#418THERAPEUTIC OLIGONUCLEOTIDES
#419MicroRNA-328 anti-sense composition and therapeutic use
#420Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#421Inhibition of microRNA-134 for the treatment of seizure-related disorders and neurologic injuries
#422Albumin production and cell proliferation
#423Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
#424Micromirs
#425Pharmaceutical Composition
#426Arrays of memory cells individually comprising a capacitor and an elevationally-extending transistor, methods of forming a tier of an array of memory cells, and methods of forming an array of memory cells individually comprising a capacitor and an elevationally-extending transistor
#427MicroRNA inhibition for the treatment of inflammation and myeloproliferative disorders
#428Cancer specific-splicing ribozyme and use thereof
#429Methods of making and using live attenuated viruses
#430Antisense oligonucleotides for treatment of cancer stem cells
#431Targeting microRNAs for metabolic disorders
#432Micro-RNA family that modulates extracellular matrix genes and uses thereof
#433P-ethoxy nucleic acids for liposomal formulation
#434MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
#435Inhibition of lncRNA HOTAIR and related materials and methods
#436Compounds and methods for increasing antisense activity
#437Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
#438Targeting microRNAs for the treatment of liver cancer
#439BIVALENT ANTISENSE OLIGONUCLEOTIDES
#440MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
#441REGULATION OF MIR-33 MICRORNAS IN THE TREATMENT OF CHOLESTEROL-RELATED DISORDERS
#442Thrombus imaging aptamers and methods of using same
#443LncRNA serves as a biomarker and therapeutic target
#444Methods of inducing insulin production
#445Segmented micro RNA mimetics
#446Treatment of Cancers with Micro-RNA Inhibitors
#447RNA nanoparticles and method of use thereof
#448Modulation of huntingtin expression
#449POLYNUCLEOTIDE-POLY(DIOL) CONJUGATES, PROCESS OF PREPARATION AND USES THEREOF
#450Methods of using PVT1 exon 9 to diagnose and treat prostate cancer
#451Method for blocking miRNA
#452Micro-RNA inhibitors and their uses in disease
#453Plasmonic nanoparticle immunoassay method
#454Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
#455miRNA modulators of thermogenesis
#456Compositions and methods for inhibition of nucleic acids function
#457Therapeutic nanoparticles and methods of use thereof
#458INHIBITORS OF MIR-17-92 CLUSTER FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA AND OTHER MALIGNANCIES
#459Preeclampsia
#460Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
#461Compositions and methods for modulating TTR expression
#462Pericyte Long Non-Coding RNAs
#463Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
#464Oligonucleotide compositions and uses thereof
#465COATED CHITOSAN-BASED POLYPLEX FOR DELIVERY OF NUCLEIC ACIDS
#466MICRORNAS IN NEURODEGENERATIVE DISORDERS
#467Recombinant AAV variants and uses thereof
#468Long Non-Coding RNA For The Treatment Of Endothelial Dysfunction
#469Circular RNA For The Diagnosis Of Cardiovascular And Inflammatory Diseases
#470Methods and agents to increase therapeutic dystrophin expression in muscle
#471Oligonucleotide compositions and methods of making the same
#472Oligonucleotide compositions and methods of making the same
#473Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
#474Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#475Recombinant DNA constructs and methods for controlling gene expression
#476Composition for reducing cellular senescence level including activity inhibitor inhibiting DCUN1D3 activity or expression inhibitor inhibiting expression of DCUN1D3-encoding gene and use thereof
#477Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
#478Reducing intron retention
#479COMPOSITIONS AND METHODS
#480Method for identification of anti-HIV human miRNA mimics and miRNA inhibitors and anti-HIV pharmaceutical compounds
#481Methods for treatment of alport syndrome
#482REVERSIR TM COMPOUNDS
#483Treatment of angiogenesis disorders
#484Treatment and prevention of thrombosis using an anti-miR
#485OLIGONUCLEOTIDE PROBES AND USES THEREOF
#486Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
#487Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#488Factor V/Va-targeting aptamer compositions and methods of using the same
#489TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA
#490Poly oligomer compound with biocleavable conjugates
#491Methods for the prevention and the treatment of extracapillary glomerulonephritis
#492Methods for modulating ATRX-dependent gene repression
#493MIR-214 AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER SPECIFIC FOR ULCERATIVE COLITIS AND A MIR-214 INHIBITOR FOR TREATMENT OF SAME
#494LONG ACTING PHARMACEUTICAL COMPOSITIONS FOR HEPATITIS C
#495Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
#496Selective Reactivation of Genes on the Inactive X Chromosome
#497Albumin production and cell proliferation
#498Combination long acting compositions and methods for Hepatitis C
#499LncRNA and oncolytic adenovirus, and application thereof
#500Microrna inhibitor system and methods of use thereof
#501MiRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
#502MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
#503Enhancing dermal wound healing by downregulating microRNA-26a
#504Intergenic RNAS and methods for modulating gene expression and pathogenesis in
#505NOVEL FUSION-CIRCULAR RNAs AND USES THEREOF
#506Antisense RNA for Treating Cancer and Inhibition of Metastasis and Vectors for Antisense Sequestration
#507Downregulating miR-132 for the treatment of lipid related disorders
#508Methods Of Inhibiting Tumorigenesis In Colon Adenocarcinoma And Compositions Therefor
#509Compositions and methods for treating vascular disorders
#510Methods and pharmaceutical compositions for treatment of cystic fibrosis
#511Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#512Next generation RNA-sequencing and long non-coding RNA in glioblastoma multiforme
#513Modified antimir-138 oligonucleotides
#514Treatment and biomarker for pulmonary hypoplasia in congenital diaphragmatic hernia
#515MicroRNA compounds and methods for modulating miR-21 activity
#516REGULATION OF MIR-33 MICRORNAS IN THE TREATMENT OF CHOLESTEROL-RELATED DISORDERS
#517TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#518COORDINATE CONTROL OF PATHOGENIC SIGNALING BY THE MIR-130/301 FAMILY IN PULMONARY HYPERTENSION AND FIBROPROLIFERATIVE DISEASES
#519MODULATION OF ENHANCER RNA MEDIATED GENE EXPRESSION
#520MicroRNA compounds and methods for modulating miR-122
#521Targeting microRNAs for metabolic disorders
#522miR-96-5p inhibitor and a screening method for the inhibitor
#523MORPHOLINO-MEDIATED INCREASE IN SOLUBLE FLT-1 EXPRESSION RESULTS IN DECREASED OCULAR AND TUMOR NEOVASCULARIZATION
#524Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
#525Multimetric oligonucleotide compounds
#526RNA EDITING BIOMARKERS FOR DIAGNOSIS, PHARMACOLOGICAL SCREENING AND PROGNOSTICATION IN CANCER
#527LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
#528PHARMACEUTICAL COMPOSITIONS COMPRISING RNA AND USE FOR TREATING CANCER
#529Delivery of agents using interfering nanoparticles
#530MIR-21-3P INHIBITORS IN SKIN DISORDERS
#531Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#532Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
#533miRNAs as novel therapeutic targets and diagnostic biomarkers for parkinson's disease
#534Modified oligonucleotides for telomerase inhibition
#535Inhibitors of metastasis
#536REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF
#537p-Ethoxy nucleic acids for liposomal formulation
#538Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (miR145) and micro-RNA 212 (miR212)
#539Compounds and methods for enhanced cellular uptake
#540Neurotensin-induced tumor formation is regulated by micro RNA 133A-aftiphilin-dependent receptor recycling
#541Methods for enhancing or decreasing the levels of MIR124 and MIR29 in subjects with muscular dystrophy
#542Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
#543Treatment for conditions associated with fibrosis and collagen deposition
#544Targeting microRNAs for metabolic disorders
#545MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1
#546Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
#547VASCULAR RE-MODELLING
#548Polycomb-associated non-coding RNAs
#549miRNAs Enhancing Cell Productivity
#550SARNA COMPOSITIONS AND METHODS OF USE
#551tRNA derived small RNAs (tsRNAs) involved in cell viability
#5522′/3′/5′-(R/S)-serinyl functionalized oligonucleotides
#553Methods targeting miR-128 for regulating cholesterol/lipid metabolism
#554MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Ovarian Cancer Using a Real-Time PCR Platform
#555NEAT1 as a prognostic marker and therapeutic target for prostate cancer
#556LncRNAs for therapy and diagnosis of angiogenesis
#557OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
#558Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#559Polycomb-associated non-coding RNAs
#560Biomarkers and therapeutic targets for abnormal retinal pigment epithelium
#561Polycomb-associated non-coding RNAs
#562COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN CANCER
#563Compositions and methods for inhibition of nucleic acids function
#564Inhibition of NEAT1 for treatment of solid tumors
#565DOWNREGULATION OF miR-7 FOR PROMOTION OF BETA CELL DIFFERENTIATION AND INSULIN PRODUCTION
#566MiRNA modulators of thermogenesis
#567Methods and Compositions Related To miR-21 and miR-29A, Exosome Inhibition And Cancer Metastasis
#568Polycomb-associated non-coding RNAS
#569Methods of Manipulating the Fate of Cells
#570Micro-RNA inhibitor
#571METHODS OF USING STRUCTURALLY INTERACTING RNA
#572Inhibition of microRNA-134 for the treatment of seizure-related disorders and neurologic injuries
#573DIFFERENTIALLY EXPRESSED MICRORNA MOLECULES FOR THE TREATMENT AND DIAGNOSIS OF CANCER
#574COMPOSITIONS AND METHODS OF USING MICRORNA INHIBITORS
#575Treatment of disease by modulation of SIRT6
#576miR-29 mimics and uses thereof
#577miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
#578Polycomb-associated non-coding RNAs
#579Compositions and methods for treating liver injury
#580MicroRNA-Based Methods and Assays for Osteosarcoma
#581THERAPEUTIC AND DIAGNOSTIC MOLECULES
#582Polycomb-associated non-coding RNAs
#583MODULATION OF MICRORNA-138 FOR THE TREATMENT OF BONE LOSS
#584Targeted therapeutic nucleosides and their use
#585METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL
#586Compounds of chemically modified oligonucleotides and methods of use thereof
#587LONG NON-CODING RNA SPRY4-IT1 AS A DIAGNOSTIC AND THERAPEUTIC AGENT
#588Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
#589MICRORNA MODULATION OF ARTHEROSCLEROSIS AND USES THEREOF
#590Methods for the prevention and the treatment of extracapillary glomerulonephritis
#591MicroRNA compounds and methods for modulating miR-21 activity
#592Small interfering RNAs with target-specific seed sequences
#593Oligonucleotide-based inhibitors comprising locked nucleic acid motif
#594Use of miRNA-214 inhibitor in inhibiting regulatory cells
#595Non-coding RNA of and identification and use thereof
#596Use of miR-494 to Modulate TRAIL-induced Apoptosis through BIM Down-regulation
#597Methods for treatment of alport syndrome
#598Sequence-specific inhibition of small RNA function
#599Regulation of BARD1 expression by non-coding RNA
#600Methods of polynucleotide preparation using multivalent cation salt compositions